# Intermediate hepatocellular carcinoma (BCLC B)

Source: https://onco.cc/cancers/hcc-intermediate/  
OnCo record `hcc-intermediate` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression.

## Summary

BCLC stage B covers multinodular hepatocellular carcinoma with preserved liver function, no cancer-related symptoms and no macrovascular invasion or extrahepatic spread. The 2022 BCLC update split it into three groups: patients whose tumour burden allows downstaging or extended transplant criteria, those with well-defined nodules suited to transarterial chemoembolisation, and those with diffuse, infiltrative or bilobar disease who do better moving straight to systemic therapy, a change described as treatment stage migration.

Transarterial chemoembolisation delivers chemotherapy-loaded particles or drug-eluting beads into the arteries feeding the tumours and blocks them; two randomised trials in 2002 (Llovet in Barcelona and Lo in Hong Kong) showed it prolongs survival, and it has been the standard since. Radioembolisation with yttrium-90 microspheres is an alternative with fewer post-procedure symptoms, though phase 3 trials against sorafenib in more advanced disease were negative. Repeated embolisation damages the liver, so the ART and other scores guide when to stop and switch.

Two phase 3 trials published in the Lancet in 2025 added systemic therapy to chemoembolisation: EMERALD-1 combined durvalumab and bevacizumab with TACE and extended median progression-free survival from 8.2 to 15.0 months, and LEAP-012 combined lenvatinib and pembrolizumab with TACE and extended it from 10.0 to 14.6 months; overall survival was immature in both at first analysis. EMERALD-3, testing durvalumab and tremelimumab with TACE, reported a benefit in 2026. The atezolizumab-bevacizumab and other advanced-stage regimens are also used directly in patients with high tumour burden, and ongoing trials compare systemic therapy alone with the combinations.

## Fields

- Kind: Cancer
- Last checked: 2026-09-17
- Also known as: Intermediate-stage HCC; Multinodular HCC; TACE-eligible hepatocellular carcinoma; BCLC B
- Tags: subtype-page
- Group: gastrointestinal
- Burden: Multiple tumours confined to a liver that still functions, without vein invasion or spread; the most heterogeneous BCLC stage, for which the 2022 update expects a median survival above two and a half years with chemoembolisation and now systemic therapy.
- Subtypes: Multinodular HCC in a cirrhotic liver within the up-to-seven criteria (downstaging or extended transplant); Well-defined nodules suitable for TACE; Diffuse or infiltrative bilobar HCC (systemic therapy first); TACE-refractory HCC; BCLC B treated with TACE plus systemic therapy (EMERALD-1, LEAP-012)
- Biomarkers: Tumour number and size (up-to-seven and other burden criteria); Child-Pugh and ALBI liver function before and after each embolisation; Alpha-fetoprotein response; Modified RECIST response on contrast imaging; Absence of macrovascular invasion and extrahepatic spread (defines the stage)

## Standard of care

- Well-defined nodules, preserved liver function: Transarterial chemoembolisation, conventional or with drug-eluting beads, repeated on demand; radioembolisation as an alternative. ([Transarterial chemoembolisation (TACE)](https://onco.cc/technologies/tace/), [TACE (transarterial chemoembolisation)](https://onco.cc/terms/tace-term/), [Radioembolisation (TARE / SIRT, yttrium-90)](https://onco.cc/technologies/radioembolisation-tare/), [BCLC staging](https://onco.cc/terms/bclc-staging/))
- TACE plus systemic therapy: Durvalumab with bevacizumab (EMERALD-1) or lenvatinib with pembrolizumab (LEAP-012) added to TACE, where approved; durvalumab-tremelimumab with TACE after EMERALD-3. ([EMERALD-1](https://onco.cc/trials/emerald-1/), [LEAP-012](https://onco.cc/trials/leap-012/), [EMERALD-3](https://onco.cc/trials/emerald-3/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/), [TACE + immunotherapy/anti-VEGF](https://onco.cc/pairings/tace-plus-systemic/))
- High burden or diffuse disease: Systemic therapy as for advanced disease (atezolizumab-bevacizumab or durvalumab-tremelimumab) instead of embolisation. ([Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/), [IMbrave150](https://onco.cc/trials/imbrave150/), [HIMALAYA](https://onco.cc/trials/himalaya/))
- Within transplant criteria after downstaging: Chemoembolisation or radioembolisation as a bridge, then liver transplantation. ([Liver transplantation for cancer (Milan criteria and beyond)](https://onco.cc/technologies/liver-transplant-oncology/), [Bridging therapy](https://onco.cc/terms/bridging-therapy/), [Transarterial chemoembolisation (TACE)](https://onco.cc/technologies/tace/))

## State of the art

- Chemoembolisation remains the backbone, but the 2022 BCLC update sends patients with diffuse or high-burden disease straight to systemic therapy.
- EMERALD-1 and LEAP-012 are the first phase 3 trials to improve on TACE alone in twenty years.
- Whether the combinations lengthen life, not just time to progression, is still awaited.

## Open problems

- No overall survival gain yet shown for TACE combinations.
- Which patients should skip embolisation and go straight to systemic therapy.
- Liver damage from repeated embolisation limits later treatment options.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Transcatheter_arterial_chemoembolization
- EMERALD-1 (Lancet 2025): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02551-0/abstract
- LEAP-012 (Lancet 2025): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract
- BCLC 2022 update (J Hepatol): https://pubmed.ncbi.nlm.nih.gov/34801630/
- Wikipedia: https://en.wikipedia.org/wiki/Transcatheter_arterial_chemoembolization

## Connected records

- technologies: [Liver transplantation for cancer (Milan criteria and beyond)](https://onco.cc/technologies/liver-transplant-oncology/), [Radioembolisation (TARE / SIRT, yttrium-90)](https://onco.cc/technologies/radioembolisation-tare/), [Transarterial chemoembolisation (TACE)](https://onco.cc/technologies/tace/)
- terms: [BCLC staging](https://onco.cc/terms/bclc-staging/), [Bridging therapy](https://onco.cc/terms/bridging-therapy/), [TACE (transarterial chemoembolisation)](https://onco.cc/terms/tace-term/)
- trials: [EMERALD-1](https://onco.cc/trials/emerald-1/), [EMERALD-3](https://onco.cc/trials/emerald-3/), [HIMALAYA](https://onco.cc/trials/himalaya/), [IMbrave150](https://onco.cc/trials/imbrave150/), [LEAP-012](https://onco.cc/trials/leap-012/)
- pairings: [TACE + immunotherapy/anti-VEGF](https://onco.cc/pairings/tace-plus-systemic/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/hcc-intermediate.json